The Evidence Based Rheumatology Podcast

Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying…

Quick podcast this week that expands on issues I discuss in Episode 55.  Go back and listen to that one first if you have time!  I think this is an important issue and it's one I'd like to highlight.…

The podcast is back!  I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in! 

PEXIVAS has landed!  This week I go over the trial and my take on it's results.  Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick bac…

(Yet) another RCT this week!  Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a sep…

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how the…

Happy New Year!  This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line.…

This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD.  The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a …

Surprising RCT this week discussing the HOPE trial, which pitted 10mg prednisone against placebo for inflammatory hand OA. I do think this will change my practice, but in a far narrower sense than th…

Super brief "checking in" podcast this week.  In short, say "hi" at ACR, write me a review on apple podcasts, send this to a friend, and keep listening :). 

Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (…

This week I revisit an old paper - the 2013 ADACTA trial that assessed tocilizumab and adalimumab for patients who cannot take or were intolerant of MTX.  

This week I decided to discuss the question of HCQ and retinal toxicity.  It has been controversial the past few years and we're all trying to get a handle on how to approach this. The Hopkins SLE gr…

Finally got around to tackling rituximab in SLE.  This is a tough topic: lots of people feel passionately one way or another, flawed observational data supports its use, flawed RCTs did not find sign…

This week I tackle an interesting cohort study that Jack Cush (@RheumNow) mentioned in his podcast.  It's a nice opportunity to discuss bDMARDs in the "real world" (AKA Sweden).  Follow me @ebrheum a…

Finally got around to tackling the JAKi this week.  I decided to focus on SELECT-COMPARE, which pitted upadacitinib (selective JAK1 inhibitor) against adalimumab and placebo.  I briefly discuss other…

Back this week to discuss an interesting paper in the NEJM.  Lots of interesting issues, most notably historical controls and their limitations.  Find all my work at ebrheum.com! 

This week I'll discuss an important paper in systemic sclerosis, the recent SENSCIS trial that compared 150mg nitedanib to placebo.  I wind up coming down pretty hard on this drug; I think it's hype …